Compound Detail
CHEMBL611
TERAZOSIN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL611 |
| Name | TERAZOSIN |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
21
Targets
105
Activities
4
Assay Types
15
PK Parameters
20
Publications
4
Known Names
8
Indications
Molecular Properties
387.4
MW (Da)
1.06
ALogP
8
HBA
1
HBD
103.0
PSA (Ų)
0.83
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1987 |
| Availability | Prescription |
| Chirality | Racemic |
Indications
Prostatic Hyperplasia Atherosclerosis Coronary Disease Diabetes Mellitus, Type 2 Hypercholesterolemia Hypertension Carotid Stenosis Parkinson Disease
ATC Classification
G04CA03
terazosin
Level 1: GENITO URINARY SYSTEM AND SEX HORMONES
Level 2: UROLOGICALS
Activity Summary
Ki 62 meas. best 9.16
Kd 28 meas. best 10.0
IC50 11 meas. best 8.3
EC50 4 meas. best 9.3
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Unchecked CHEMBL612545 | Kd | 10.0 | 8.73 | 0.1 | 3 |
| Alpha-1B adrenergic receptor CHEMBL232 | EC50 | 9.3 | 9.03 | 0.5 | 2 |
| Alpha-1B adrenergic receptor CHEMBL3122 | Ki | 9.16 | 9.16 | 0.7 | 1 |
| Alpha-1A adrenergic receptor CHEMBL319 | Ki | 9.09 | 8.5067 | 0.8 | 3 |
| Alpha-1D adrenergic receptor CHEMBL223 | Ki | 9.07 | 8.522 | 0.8 | 10 |
| Alpha-1D adrenergic receptor CHEMBL326 | Ki | 9.0 | 8.31 | 1.0 | 3 |
| Alpha-1B adrenergic receptor CHEMBL232 | Ki | 8.92 | 8.593 | 1.2 | 10 |
| Alpha-1D adrenergic receptor CHEMBL326 | Kd | 8.83 | 8.74 | 1.5 | 4 |
| Alpha-1B adrenergic receptor CHEMBL315 | Ki | 8.72 | 8.6 | 1.9 | 2 |
| Alpha-1A adrenergic receptor CHEMBL229 | Ki | 8.7 | 8.2373 | 2.0 | 15 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | Kd | 8.65 | 8.65 | 2.2 | 1 |
| Alpha-1A adrenergic receptor CHEMBL4892 | Ki | 8.6 | 8.09 | 2.5 | 2 |
| Rattus norvegicus CHEMBL376 | Kd | 8.6 | 8.32 | 2.5 | 2 |
| Alpha-1B adrenergic receptor CHEMBL315 | Kd | 8.6 | 8.596 | 2.5 | 5 |
| Adrenergic receptor alpha-1 CHEMBL2094251 | IC50 | 8.3 | 8.3 | 5.0 | 1 |
| Alpha-1B adrenergic receptor CHEMBL315 | IC50 | 8.22 | 8.22 | 6.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL266 | Ki | 8.11 | 8.11 | 7.7 | 1 |
| Alpha-1A adrenergic receptor CHEMBL319 | Kd | 8.04 | 7.984 | 9.1 | 5 |
| Alpha-1D adrenergic receptor CHEMBL223 | IC50 | 7.77 | 7.77 | 17.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL3637 | Kd | 7.7 | 7.7 | 19.9 | 1 |
| Alpha-1A adrenergic receptor CHEMBL319 | IC50 | 7.62 | 7.62 | 24.0 | 1 |
| Adrenergic receptor alpha-1 CHEMBL2094251 | Kd | 7.6 | 7.5 | 25.1 | 2 |
| Alpha-2B adrenergic receptor CHEMBL1942 | Ki | 7.58 | 7.045 | 26.0 | 4 |
| Canis familiaris CHEMBL373 | Kd | 7.44 | 7.16 | 36.3 | 3 |
| Alpha-1A adrenergic receptor CHEMBL229 | Kd | 7.44 | 7.44 | 36.3 | 2 |
| Alpha-1A adrenergic receptor CHEMBL229 | EC50 | 7.29 | 7.29 | 51.0 | 2 |
| Alpha-2C adrenergic receptor CHEMBL1916 | Ki | 7.11 | 6.652 | 78.0 | 5 |
| Alpha-2B adrenergic receptor CHEMBL1942 | IC50 | 6.37 | 6.37 | 428.0 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | Ki | 6.26 | 5.812 | 549.5 | 5 |
| Unchecked CHEMBL612545 | Ki | 6.07 | 6.07 | 846.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.9 | 5.9 | 1269.0 | 1 |
| Alpha-2C adrenergic receptor CHEMBL1916 | IC50 | 5.22 | 5.22 | 6042.0 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | IC50 | 4.86 | 4.86 | 13832.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 4.75 | 4.75 | 17782.8 | 1 |
| Solute carrier family 22 member 1 CHEMBL5685 | IC50 | 4.62 | 4.62 | 23700.0 | 1 |
| ATP-binding cassette sub-family C member 4 CHEMBL1743128 | IC50 | 4.43 | 4.43 | 36800.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 1.1 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.1 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.1 | mL.min-1.kg-1 | Homo sapiens |
| F | 49.0 | % | Rattus norvegicus |
| F | 49.0 | % | Rattus norvegicus |
| F | 49.0 | % | Rattus norvegicus |
| F | 80.0 | % | Homo sapiens |
| Fu | 0.08 | - | Homo sapiens |
| Fu | 0.08 | - | Homo sapiens |
| MRT | 15.0 | hr | Homo sapiens |
| T1/2 | 7.5 | hr | Rattus norvegicus |
| T1/2 | 7.5 | hr | Rattus norvegicus |
| T1/2 | 7.5 | hr | Rattus norvegicus |
| T1/2 | 9.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine